Search results (1320)
« Back to PublicationsA phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours.
Steele N. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 200S - 200S
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.
Pacey S. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 205S - 205S
Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors
Blagden S. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 226S - 226S
Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.
Blagden S. et al, (2005), CLINICAL CANCER RESEARCH, 11, 9119S - 9119S
Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
Plummer ER. et al, (2005), Clin Cancer Res, 11, 3402 - 3409
Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report.
Benghiat A. et al, (2004), JOURNAL OF CLINICAL ONCOLOGY, 22, 149S - 149S
Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report.
Benghiat A. et al, (2004), J Clin Oncol, 22
Preliminary experience using high-intensity focused ultrasound for the treatment of kidney and liver tumours
Illing RO. et al, (2004), BRITISH JOURNAL OF CANCER, 91, S21 - S21
Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasound.
Kennedy JE. et al, (2004), Ultrasound Med Biol, 30, 851 - 854
DNA repair pathways in drug resistance in melanoma.
Bradbury PA. and Middleton MR., (2004), Anticancer Drugs, 15, 421 - 426
DNA repair pathways in drug resistance in melanoma
Bradbury PA. and Middleton MR., (2004), ANTI-CANCER DRUGS, 15, 421 - 426
High-intensity focused ultrasound for the treatment of liver tumours.
Kennedy JE. et al, (2004), Ultrasonics, 42, 931 - 935
Performance status score: do patients and their oncologists agree?
Blagden SP. et al, (2003), Br J Cancer, 89, 1022 - 1027
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S. et al, (2003), J Clin Oncol, 21, 2551 - 2557
Polar expeditions--provisioning the centrosome for mitosis.
Blagden SP. and Glover DM., (2003), Nat Cell Biol, 5, 505 - 511